Research programme: galectin antagonists - Unibioscreen

Drug Profile

Research programme: galectin antagonists - Unibioscreen

Alternative Names: UNBS 1070; UNBS 3976

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Unibioscreen
  • Class
  • Mechanism of Action Galectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in Belgium
  • 14 Sep 2007 The UNBS 1070 programme is available for licensing as of 14 Sep 2007. http://www.unibioscreen.com
  • 14 Sep 2007 Early research in Cancer in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top